By Dennis Thompson HealthDay ReporterTHURSDAY, April 9, 2026 (HealthDay News) — Prompt treatment with a fecal transplant can ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

A recent Centers for Disease Control and Prevention report found 75 percent of patients in a group of 10,342 cases were already colonized with C. difficile at the time of hospital admission, according ...

A person’s biology may play more of a role in how Clostridioides difficile, or C. diff, spreads more so than healthcare facility preventive measures, a new study finds. This means that transmission of ...

Researchers say the reduction was influenced by the combined effects of changes in infection prevention and control, ...

A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...

At the end of 2010, Ellis Hospital noticed a troubling spike in Clostridium difficile infections. Clostridium difficile, or C-diff, is a common cause of diarrhea acquired in healthcare settings; it ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...

Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: ...